AgomAb Therapeutics NV

AGMB

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0002020932

SEC filings (opens in a new tab)

No open-market purchases or sales by AgomAb Therapeutics NV insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $337.0M in total; no superinvestor holds it.

Q1 2026 vs. Q4 2025

How the institutions holding AgomAb Therapeutics NV changed between Q4 2025 and Q1 2026.

All holders in Q1 2026 All holders in Q4 2025

13F holders of AGMB: Q4 2025 compared with Q1 2026
Measure	Q4 2025	Q1 2026	Change
Holders	0	32	+32
Shares	0	23.4M	+23.4M
Value	$0	$245.3M	+$245.3M

New holders (32)

Institutions that held AgomAb Therapeutics NV at the end of Q1 2026 but not at the end of Q4 2025.

Institutions new to AGMB in Q1 2026
Institution	Shares	Value	% of portfolio
EQT Fund Management S.a r.l.	5,141,992	$53.9M	5.28%
Sanofi	2,783,096	$29.2M	8.69%
Cormorant Asset Management, LP	2,465,348	$25.9M	1.30%
TCG Crossover Management, LLC	2,053,233	$21.5M	0.62%
Federated Hermes, Inc.	1,618,000	$17.0M	0.03%
Casdin Capital, LLC	1,550,000	$16.3M	1.23%
Andera Partners	1,538,702	$16.1M	9.12%
FMR LLC	1,458,677	$15.3M	0.00%
Nantahala Capital Management, LLC	1,200,000	$12.9M	0.80%
Standard Life Aberdeen plc	707,656	$7.42M	0.01%
Perceptive Advisors LLC	600,000	$6.29M	0.12%
Samsara BioCapital, LLC	600,000	$6.29M	0.61%
Siren, L.L.C.	411,250	$4.31M	0.12%
LMR Partners LLP	300,000	$3.15M	0.03%
Seven Grand Managers, LLC	200,000	$2.10M	0.14%
Redmile Group, LLC	156,250	$1.64M	0.11%
Millennium Management LLC	95,233	$999.0K	0.00%
Pfizer Inc	75,000	$813.8K	0.34%
Alyeska Investment Group, L.P.	75,000	$786.8K	0.00%
Laurion Capital Management LP	50,000	$524.5K	0.05%
Bellevue Group AG	50,000	$524.5K	0.01%
Sectoral Asset Management Inc	43,500	$477.3K	0.40%
Goldman Sachs Group Inc	35,739	$374.9K	0.00%
Citadel Advisors LLC	35,000	$367.1K	0.00%
Burkehill Global Management, LP	35,000	$367.1K	0.02%
HRT Financial LP	23,726	$248.0K	0.00%
D. E. Shaw & Co., Inc.	15,326	$160.8K	0.00%
Two Sigma Investments, LP	14,241	$149.4K	0.00%
Jane Street Group, LLC	12,794	$134.2K	0.00%
UBS Group AG	6,437	$67.5K	0.00%
Morgan Stanley	3,025	$31.7K	0.00%
SBI Securities Co., Ltd.	2	$21	0.00%

Sold out (0)

Institutions that held AgomAb Therapeutics NV at the end of Q4 2025 and filed for Q1 2026 without it.

None.